EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease

Gabriela O Girón, Sergi Otero iD, Panagiota Efstathia Nikolaou, Sebastià Alcover, Lisaidy Ramos-Regalado, Carlos Zaragoza iD, Luca Liberale iD, María Borrell-Pages iD, Teresa Padró iD, Rosa Suades iD, Gemma Vilahur iD

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70167 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Gabriela O Girón und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sant Pau Research Institute (IR-SANT PAU), Barcelona, Spain. Hauptthemen laut MEDLINE: Dyslipidemias, Atherosclerosis, Cardiovascular Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 210 Literaturangaben. Gefördert von: Agencia Estatal de Investigación, Fundació la Marató de TV3, European Cooperation in Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A significant proportion of patients continue to experience cardiovascular (CV) events despite achieving recommended low‐density lipoprotein cholesterol (LDL‐C) targets, a phenomenon referred to as residual CV risk.

Methods

Clinical evidence from large outcome trials highlights the impact of residual risk on cardiovascular disease (CVD) burden, underscoring the need for therapeutic strategies beyond LDL‐C lowering. Residual CV risk arises from diverse mechanisms, including persistent atherogenic dyslipidaemia [elevated triglyceride‐rich lipoproteins (TRL), high triglycerides (TG), low high‐density lipoprotein cholesterol (HDL‐C) levels and increased apolipoprotein B (ApoB), Lipoprotein(a) (Lp[a]) and non‐HDL‐C], chronic inflammation, metabolic disorders and a prothrombotic state. These abnormalities continue to drive atherosclerotic progression in optimally treated patients, underscoring that managing residual CV risk requires a multifaceted approach.

Results

Lifestyle and dietary interventions remain foundational, targeting weight reduction, smoking cessation or adoption of a Mediterranean diet. Pharmacological options include statins (as first‐line therapy), or the use of ezetimibe, or bempedoic acid since they both have complementary effects to LDL‐C lowering. Emerging therapies, including proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein C‐III (ApoC3) and angiopoietin‐like 3 (ANGPTL3) inhibitors, demonstrate potential efficacy in favourably modulating lipid profiles and targeting specific components of atherogenic dyslipidaemia (AD). Combination therapies tailored to individual lipid profiles show promise to reduce residual CV risk.

Conclusion

The following review aims to provide a comprehensive overview of the latest evidence on the factors driving residual CV risk and the therapeutic interventions available to treat atherogenic dyslipidaemia beyond LDL‐C reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DyslipidemiasAtherosclerosisCardiovascular DiseasesHumansCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsTriglyceridesAnticholesteremic AgentsApolipoproteins BHypolipidemic AgentsHeart Disease Risk FactorsEzetimibeCholesterol, HDLLipoprotein(a)PCSK9 InhibitorsLipoproteinsProprotein Convertase 9

Stichwörter der Autor:innen

cardiovascular diseaseclinical trialsdyslipidemiaresidual cardiovascular risktherapeutic

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsTriglyceridesAnticholesteremic AgentsApolipoproteins BHypolipidemic AgentsEzetimibeCholesterol, HDLLipoprotein(a)PCSK9 Inhibitors

Autor:innen und Institutionen

  • Sant Pau Research Institute (IR-SANT PAU), Barcelona, Spain.
  • Facultat de Biociències, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Laboratory of Pharmacology, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Clinical Therapeutics, Department of Medicine, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
  • Facultat de Biologia, Universitat de Barcelona (UB), Barcelona, Spain.
  • Unidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, Madrid, Spain.

ORCID-Profile: Sergi Otero, Carlos Zaragoza, Luca Liberale, María Borrell-Pages, Teresa Padró, Rosa Suades, Gemma Vilahur

Förderung

  • Agencia Estatal de Investigación
  • Fundació la Marató de TV3
  • European Cooperation in Science and Technology
  • Generalitat de Catalunya
  • Instituto de Salud Carlos III
  • COST action EU-METAHEART

Zitieren

APA

Girón, G. O., Otero, S., Nikolaou, P. E., Alcover, S., Ramos-Regalado, L., Zaragoza, C., Liberale, L., Borrell-Pages, M., Padró, T., Suades, R., & Vilahur, G. (2026). Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70167

Vancouver

Girón GO, Otero S, Nikolaou PE, Alcover S, Ramos-Regalado L, Zaragoza C, et al. Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70167

BibTeX
@article{Girn2026,
  author = {Girón, Gabriela O and Otero, Sergi and Nikolaou, Panagiota Efstathia and Alcover, Sebastià and Ramos-Regalado, Lisaidy and Zaragoza, Carlos and Liberale, Luca and Borrell-Pages, María and Padró, Teresa and Suades, Rosa and Vilahur, Gemma},
  title = {Atherogenic dyslipidaemia and residual cardiovascular risk: Understanding the link to heart disease},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70167}
}
Kostenlos starten →